Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 10/20 | 0.82 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.69 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460276 | 0.91 | P2RX1 (0.77) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL2169619 | 0.90 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL29454776 | 0.90 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438815 | 0.88 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL23685650 | 0.88 | P2RX1 (0.82) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL11932157 | 0.88 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL24438716 | 0.87 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL30692659 | 0.87 | P2RX1 (0.87) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL21021862 | 0.87 | PLAU (0.73) | P2RX1TMPRSS4LMNAHTTSMN1; SMN2 | |
| SCHEMBL13189548 | 0.86 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | claimed |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-11529361-B2 | Halogenated salicylanilides for treating Clostridium infections | UNION therapeutics A/S (DK) | 2022-12-20 | — | — | US | disclosed |
| WO-2022109148-A1 | SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210308153-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | UNION therapeutics A/S (DK) | 2021-10-07 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3302492-B1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | UNION THERAPEUTICS AS (DK) | 2021-03-17 | — | — | EP | disclosed |
| US-10857164-B2 | Halogenated salicylanilides for treating Clostridium infections | UNION therapeutics A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| US-20200093839-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | UNION therapeutics A/S (DK) | 2020-03-26 | — | — | US | disclosed |
| US-10463680-B2 | Halogenated salicylanilides for treating clostridium infections | UNION therapeutics A/S (DK) | 2019-11-05 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| US-20180207179-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | Antibiotx A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-20180207179-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | Antibiotx A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| WO-2016193136-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | ANTIBIOTX APS (DK) | 2016-12-08 | — | — | WO | disclosed |
| US-7547804-B2 | Compounds, compositions, and methods employing same | MYRIAD GENETICS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547804-B2 | Compounds, compositions, and methods employing same | MYRIAD GENETICS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | ACE2, ACE, TMPRSS2 | P2RX1 2669/4885TMPRSS4 14/4885P2RX4 3287/4885 |
| US-10463680-B2 | Halogenated salicylanilides for treating clostridium infections | SLC10A2, FABP2, SI | P2RX1 4148/4885TMPRSS4 2867/4885P2RX4 3940/4885 |
| US-10857164-B2 | Halogenated salicylanilides for treating Clostridium infections | SLC10A2, FABP2, SI | P2RX1 4219/4885TMPRSS4 2812/4885P2RX4 4028/4885 |
| US-20210308153-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | SLC10A2, FABP2, SI | P2RX1 4219/4885TMPRSS4 2812/4885P2RX4 4028/4885 |
| US-11529361-B2 | Halogenated salicylanilides for treating Clostridium infections | SLC10A2, FABP2, SI | P2RX1 4219/4885TMPRSS4 2812/4885P2RX4 4028/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | P2RX1 4516/4885TMPRSS4 3058/4885P2RX4 4328/4885 |
| US-20180207179-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | SLC10A2, FABP2, SI | P2RX1 4219/4885TMPRSS4 2812/4885P2RX4 4028/4885 |
| US-20200093839-A1 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS | SLC10A2, FABP2, SI | P2RX1 4219/4885TMPRSS4 2812/4885P2RX4 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.